INVOKANA PI PDF

Learn about INVOKANA®, an SGLT2 inhibitor that helps lower blood sugar and risk of cardiovascular disease in adults. See full Prescribing & Safety Info. INVOKANA is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an INVOKANA mg once daily who have an eGFR of 60 mL/min/ m2. INVOKANA® is now the only oral diabetes treatment approved to in the INVOKANA® U.S. full Prescribing Information (PI).3 The PI also.

Author: Tohn Vudocage
Country: Jamaica
Language: English (Spanish)
Genre: Software
Published (Last): 4 July 2012
Pages: 405
PDF File Size: 5.94 Mb
ePub File Size: 13.5 Mb
ISBN: 912-9-65503-738-8
Downloads: 26325
Price: Free* [*Free Regsitration Required]
Uploader: Ketaxe

TGA eBS – Product and Consumer Medicine Information

The PBAC noted a substantially higher incidence of both invokaan and female genital mycotic infections and osmotic diuresis related adverse events in the canagliflozin arms compared to sitagliptin.

The PBAC considered that as patients with diabetes will have regular monitoring of renal function as part of standard care, the omission of costs for such monitoring were appropriately excluded. Appropriate diagnostic testing should be considered, e. To view content sources and attributions, please refer to our editorial policy. Obtain an eGFR before initiation and at least annually thereafter, and more frequently in patients at increased risk of renal impairment.

When someone is first diagnosed with type 2 diabetes, they will not typically start with Invokana alone as an initial treatment. Consider prescribing short- and long-acting bronchodilators and inhaled corticosteroids for patients with chronic obstructive pulmonary disease. Median time to complete resolution of neutropenia was 13 days range: Signs of low blood sugar include:. The median onset was day Surgery and Other Procedures: Your insurance may cover all or some ibvokana the cost of this medication.

Most Related  EUSEBIO RUVALCABA UN HILITO DE SANGRE PDF

In clinical trials, the invkana of malignancies other than lymphoma and non-melanoma skin cancer per patient-years of follow-up was 0. If neurological compromise is noted, urgent treatment is necessary.

Indication and Important Safety Information

Control hypertension and correct hypokalemia before and during pj. Rarely, treatment with TNF blockers may result in a lupus-like syndrome. The submission presented a cost-minimisation analysis, based on non-inferiority claim of canagliflozin mg to sitagliptin mg for mean reduction in HbA1c from baseline. Neutropenic sepsis, including fatal cases, can occur.

The PBAC considered that canagliflozin should be treated as interchangeable on an individual patient basis with dapagliflozin.

Severe acute exacerbations of hepatitis B e.

If you are not able to afford your medication, do not hesitate to speak to your doctor about this. Before initiating, consider factors in the patient history that may predispose to the need for amputations, such as a history of prior amputation, peripheral vascular disease, neuropathy, and diabetic foot ulcers.

Canagliflozin, tablet, 100 mg and 300 mg, Invokana® – July 2013

A higher rate of serious infections has also been observed in RA patients treated with rituximab who received subsequent treatment with a TNF blocker. In patients with chronic kidney disease, also assess serum phosphorus.

All claims and other submissions to payers should be in compliance with all applicable requirements. The PBAC therefore considered that canagliflozin was non-inferior to sitagliptin with respect to efficacy. RPLS can present with headache, seizures, confusion, and visual disturbances.

Patients should be monitored closely. Other options include glucagon like peptide 1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and thiazolidinediones. However, in Maythe Invooana issued an important warning that the SGLT2 inhibitors like canagliflozin can infrequently cause ketoacidosis, usually in less than 1 out of every patients.

Most Related  CARTEA CELOR CINCI CERCURI PDF

The malignancies occurred after a median of 30 months after the first dose of therapy. Also, the FDA warned that patients taking canaglifozin should notify their doctor right away if they notice any new pain, tenderness, sores, ulcers, or infections in their legs or feet. Department of Health Department of Health and Ageing. Clinical presentations included cough, dyspnea, and interstitial infiltrates following one to three doses.

RxEconsult | Home

In clinical trials of all TNF inhibitors, more cases of lymphoma were observed compared with controls and the expected rate in the general population. Serious urinary tract infections UTI have occurred with this class of medications; contact your doctor if you have any symptoms of a UTI, such as:. Please refer to the full Prescribing Information or a complete list of adverse drug reactions. Low blood sugar is not common with normal doses of Invokana.

Discontinue following the completion of a chemotherapy course.

Consider supportive care with transfusions. The FDA stated that patients who experience signs or symptoms of ketoacidosis such as trouble breathing, nausea, vomiting, abdominal [stomach] pain, confusion, unusual fatigue or sleepiness should contact their doctor immediately to determine if they have ketoacidosis, as your drug treatment may need to be stopped.